Informations sur le produit
- [1,1′-Biphenyl]-3-carboxamide, N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4′-(trifluoromethoxy)-, rel-, phosphate (1:2)
- LDE 225 phosphate
- Odomzo
Sonidegib phosphate is an inhibitor of receptor tyrosine kinase, which is a protein that stimulates the growth and division of cells. Sonidegib phosphate binds to PD-L1, which is a receptor for the cytokine interleukin-2 (IL-2), and inhibits its activity. It also binds to metal ions such as zinc and copper, inhibiting their ability to stimulate cell division. Sonidegib phosphate has been shown to be safe in clinical trials with no significant side effects observed. It can be used alone or in combination with oral itraconazole for treating cancer. The drug's mechanism of action is currently unknown; however, it may modulate the immune response by reducing the expression of messenger RNA (mRNA) for IL-2 and other cytokines.